| Pain Flare‐Effect Prophylaxis With Corticosteroids on Bone Radiotherapy Treatment: A Systematic Review C Fabregat, S Almendros, A Navarro‐Martin, J Gonzalez Pain Practice 20 (1), 101-109, 2020 | 12 | 2020 |
| Advances in the systemic treatment of therapeutic approaches in biliary tract cancer O Mirallas, D López-Valbuena, D García-Illescas, C Fabregat-Franco, ... ESMO open 7 (3), 100503, 2022 | 11 | 2022 |
| Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma M Rimini, T Macarulla, V Burgio, S Lonardi, M Niger, M Scartozzi, ... European Journal of Cancer 171, 232-241, 2022 | 9 | 2022 |
| Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study E Fonseca, JM Cabrera-Maqueda, R Ruiz-García, L Naranjo, ... The Lancet Neurology 22 (12), 1150-1159, 2023 | 7 | 2023 |
| Clinical and genomic characterisation of early-onset pancreatic cancer F Castet, C Fabregat-Franco, G Castillo, V Navarro, A Sierra, DA Acosta, ... European Journal of Cancer 194, 113338, 2023 | 6 | 2023 |
| Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters M Rimini, E Loi, C Fabregat-Franco, V Burgio, S Lonardi, M Niger, ... European Journal of Cancer 175, 299-310, 2022 | 6 | 2022 |
| Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis L Vidal, E Pando, L Blanco, C Fabregat–Franco, F Castet, A Sierra, ... Cancer Treatment Reviews, 102604, 2023 | 5 | 2023 |
| Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases C Fabregat-Franco, A Stradella, V Navarro, J Linares, M Galdeano, ... Clinical and Translational Oncology 23, 1761-1768, 2021 | 4 | 2021 |
| Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation Q Serra-Camprubí, H Verdaguer, W Oliveros, N Lupión-Garcia, ... Clinical Cancer Research 29 (2), 432-445, 2023 | 3 | 2023 |
| Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma M Rimini, C Fabregat-Franco, V Burgio, S Lonardi, M Niger, M Scartozzi, ... Scientific Reports 12 (1), 18775, 2022 | 3 | 2022 |
| Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles. M Domenech, C Fabregat-Franco, C Mesia, A Esteve, SDB Berron, ... Journal of Clinical Oncology 39 (15_suppl), 2013-2013, 2021 | 2 | 2021 |
| RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or … C Fabregat-Franco, C Yoo, B Sangro, C Qvortrup, HD Kim, T Macarulla, ... Cancer Research 83 (7_Supplement), 2342-2342, 2023 | 1 | 2023 |
| Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients M Rimini, C Fabregat-Franco, M Persano, V Burgio, F Bergamo, M Niger, ... Targeted Oncology 18 (1), 139-145, 2023 | 1 | 2023 |
| FGFR2 fusion detection in plasma: A new era in the clinical monitoring of iCCA. A Gonzalez-Medina, H Verdaguer, M Vila-Casadesús, A Sierra, G Castillo, ... Journal of Clinical Oncology 40 (16_suppl), 4085-4085, 2022 | 1 | 2022 |
| KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma. C Fabregat-Franco, J Matito, A Martin, H Verdaguer, F Castet, JMM Aymar, ... Journal of Clinical Oncology 40 (16_suppl), e16302-e16302, 2022 | 1 | 2022 |
| Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study … V Pacheco-Barcia, A Mariño Méndez, A Carmona-Bayonas, J Gallego, ... Journal of Clinical Oncology 42 (3_suppl), 623-623, 2024 | | 2024 |
| Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis NS Tissera, M Chiaravalli, A Turpin, R Luca, F Castet, C Fabregat-Franco, ... ESMO Gastrointestinal Oncology 2, 100011, 2023 | | 2023 |
| 1636P Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application L Ghiglione, FJM i Carrillo, FM Esposito, DP Coronel, MD Delcuratolo, ... Annals of Oncology 34, S905, 2023 | | 2023 |
| 1650P Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset DAA Eyzaguirre, C Fabregat-Franco, F Castet, DEL Valbuena, G Castillo, ... Annals of Oncology 34, S910, 2023 | | 2023 |
| 1686TiP Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations T Macarulla, F Castet, ML de Mena, R Garcia-Carbonero, EM de Castro, ... Annals of Oncology 34, S923, 2023 | | 2023 |
